These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 33356786)

  • 1. Metabolism meets apoptosis in AML.
    Timofeeva N; Gandhi V
    Leuk Lymphoma; 2021 Mar; 62(3):514-516. PubMed ID: 33356786
    [No Abstract]   [Full Text] [Related]  

  • 2. Differentiation of acute myeloid leukemia (AML) cells with ATRA reduces
    Buschner G; Feuerecker B; Spinner S; Seidl C; Essler M
    Leuk Lymphoma; 2021 Mar; 62(3):630-639. PubMed ID: 33140666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BH3 mimetic ABT-737 induces apoptosis in CD34
    Rao J; Li F; Zhang RY; Zhou HH; Chen GA
    Asia Pac J Clin Oncol; 2017 Apr; 13(2):e144-e152. PubMed ID: 26552712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
    Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
    Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.
    Ruvolo PP; Ruvolo VR; Benton CB; AlRawi A; Burks JK; Schober W; Rolke J; Tidmarsh G; Hail N; Davis RE; Andreeff M
    Biochim Biophys Acta; 2016 Apr; 1863(4):562-71. PubMed ID: 26704388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
    Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
    Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
    Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
    Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of the sensitivity of dormant AML cells to the BAD mimetics ABT-199 and ABT-737.
    Yu N; Seedhouse C; Russell N; Pallis M
    Leuk Lymphoma; 2018 Oct; 59(10):2447-2453. PubMed ID: 29431553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
    van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
    Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
    O' Reilly E; Dhami SPS; Baev DV; Ortutay C; Halpin-McCormick A; Morrell R; Santocanale C; Samali A; Quinn J; O'Dwyer ME; Szegezdi E
    Sci Rep; 2018 Oct; 8(1):15752. PubMed ID: 30361682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737.
    Krystal GW
    Cancer Biol Ther; 2010 Nov; 10(9):930-2. PubMed ID: 20935462
    [No Abstract]   [Full Text] [Related]  

  • 15. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis.
    Meynet O; Bénéteau M; Jacquin MA; Pradelli LA; Cornille A; Carles M; Ricci JE
    Leukemia; 2012 May; 26(5):1145-7. PubMed ID: 22076465
    [No Abstract]   [Full Text] [Related]  

  • 16. ABT-737, proving to be a great tool even before it is proven in the clinic.
    Vaux DL
    Cell Death Differ; 2008 May; 15(5):807-8. PubMed ID: 18408737
    [No Abstract]   [Full Text] [Related]  

  • 17. A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia.
    Lappin KM; Davis L; Matchett KB; Ge Y; Mills KI; Blayney JK
    Sci Rep; 2020 Oct; 10(1):18514. PubMed ID: 33116257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-apoptotic Bcl-XL but not Mcl-1 contributes to protection against virus-induced apoptosis.
    Ohmer M; Weber A; Sutter G; Ehrhardt K; Zimmermann A; Häcker G
    Cell Death Dis; 2016 Aug; 7(8):e2340. PubMed ID: 27537523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines.
    Ryu Y; Hall CP; Reynolds CP; Kang MH
    Exp Biol Med (Maywood); 2014 Oct; 239(10):1390-402. PubMed ID: 24951472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.